Mark Sutherland
Impact in
- Immunology top 10%
- Toxin Mechanisms and Immunotoxins
- Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism
Papers in
-
- Cancer therapeutics and mechanisms 5
- Natural product bioactivities and synthesis 4
- Glycosylation and Glycoproteins Research 3
- Immunology 12
- Toxin Mechanisms and Immunotoxins 11
- Co-authors
- Hendrik Fuchs (13 shared papers)Christopher Bachran (11 shared papers)Iring Heisler (7 shared papers)Diana Bachran (6 shared papers)Steven D. Shnyder (13 shared papers)Laurence H. Patterson (14 shared papers)Matthias F. Melzig (4 shared papers)T Schewe (4 shared papers)
- Journals
- Cancer Research (4 papers)PLoS ONE (2 papers)Journal of Controlled Release (2 papers)Cancers (2 papers)Life Sciences (2 papers)
- Partner nations
- United KingdomGermanyUnited States
In The Last Decade
Mark Sutherland
39 papers receiving 922 citations
Peers
Comparison fields: 5 of 91
- Immunology 271
- Pharmacology 113
- Biotechnology 91
- Biochemistry 62
- Molecular Biology 544
Countries citing papers authored by Mark Sutherland
This map shows the geographic impact of Mark Sutherland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Sutherland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Sutherland more than expected).
Fields of papers citing papers by Mark Sutherland
This network shows the impact of papers produced by Mark Sutherland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Sutherland. The network helps show where Mark Sutherland may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Sutherland, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2008 | 91 | |
| 2 | 2002 | 89 | |
| 3 | 2009 | 64 | |
| 4 | 2012 | 56 | |
| 5 | 2005 | 55 | |
| 6 | 2013 | 50 | |
| 7 | 2006 | 47 | |
| 8 | 2000 | 43 | |
| 9 | 2002 | 40 | |
| 10 | 2012 | 36 | |
| 11 | 1998 | 36 | |
| 12 | 2006 | 34 | |
| 13 | 2009 | 33 | |
| 14 | 2011 | 30 | |
| 15 | 2013 | 29 | |
| 16 | 2000 | 27 | |
| 17 | 1999 | 24 | |
| 18 | 2022 | 22 | |
| 19 | 2002 | 19 | |
| 20 | 2009 | 18 |
About Mark Sutherland
Mark Sutherland is a scholar working on Molecular Biology, Immunology, Oncology, Pharmacology and Neurology, having authored 39 papers that have together received 949 indexed citations. Recurring topics across this work include Toxin Mechanisms and Immunotoxins (11 papers), Pharmacogenetics and Drug Metabolism (5 papers), Cancer therapeutics and mechanisms (5 papers), Neuroblastoma Research and Treatments (4 papers), Natural product bioactivities and synthesis (4 papers), Cell Adhesion Molecules Research (4 papers), Glycosylation and Glycoproteins Research (3 papers) and Transgenic Plants and Applications (3 papers). The work is most often cited by research in Immunology (271 citations), Pharmacology (113 citations), Biotechnology (91 citations), Biochemistry (62 citations) and Molecular Biology (544 citations). Mark Sutherland has collaborated with scholars based in United Kingdom, Germany and United States. Frequent co-authors include Hendrik Fuchs, Christopher Bachran, Iring Heisler, Diana Bachran, Steven D. Shnyder, Laurence H. Patterson, Matthias F. Melzig, T Schewe, Santosh Nigam and R Tauber. Their work appears in journals such as Cancer Research, PLoS ONE, Journal of Controlled Release, Cancers and Life Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.